Figures & data
Table 1 Demographic characteristics of human islet donors
Figure 1 Blood glucose and body weights of control and lixisenatide-treated mice engrafted with human islets.
Abbreviations: NSG RIP-DTR, nonobese diabetic–severe combined immunodeficiency (NOD–scid) IL-2 receptor common gamma chain (IL-2rgnull) rat insulin promoter-diphtheria toxin receptor; SEM, standard error of mean; sc, subcutaneously.
![Figure 1 Blood glucose and body weights of control and lixisenatide-treated mice engrafted with human islets.](/cms/asset/7b2ec39f-a9fa-4be4-b118-99b9b029160e/dmso_a_87253_f0001_c.jpg)
Figure 2 Lixisenatide treatment improves recovery from hyperglycemia in human islet-engrafted mice.
Abbreviation: NSG RIP-DTR, nonobese diabetic–severe combined immunodeficiency (NOD–scid) IL-2 receptor common gamma chain (IL-2rgnull) rat insulin promoter-diphtheria toxin receptor.
![Figure 2 Lixisenatide treatment improves recovery from hyperglycemia in human islet-engrafted mice.](/cms/asset/7270755e-0172-40d7-a73b-b556dd8e37d2/dmso_a_87253_f0002_c.jpg)
Figure 3 Fasting and glucose-stimulated human insulin levels and stimulation indices in control and lixisenatide-treated mice engrafted with human islets.
Abbreviations: ip, intraperitoneal; SEM, standard error of mean.
![Figure 3 Fasting and glucose-stimulated human insulin levels and stimulation indices in control and lixisenatide-treated mice engrafted with human islets.](/cms/asset/b0b1b33b-dfa8-4c8c-a33a-c9c1de3c5125/dmso_a_87253_f0003_b.jpg)
Figure 4 GTTs in control and lixisenatide-treated mice engrafted with human islets.
Abbreviations: GTT, glucose tolerance test; SEM, standard error of mean.
![Figure 4 GTTs in control and lixisenatide-treated mice engrafted with human islets.](/cms/asset/209209e4-f732-42cf-8f3e-97d16325b634/dmso_a_87253_f0004_c.jpg)
Figure 5 Percent TUNEL-positive human beta cells in islet grafts recovered from control and lixisenatide-treated mice.
Abbreviations: SEM, standard error of mean; TUNEL, terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling.
![Figure 5 Percent TUNEL-positive human beta cells in islet grafts recovered from control and lixisenatide-treated mice.](/cms/asset/34190400-17bb-44ae-9d85-46834dc3f508/dmso_a_87253_f0005_b.jpg)
Figure 6 Percent human beta- and alpha-cell proliferation in each islet graft recovered from control and lixisenatide-treated mice.
Abbreviation: BrdU+, bromodeoxyuridine positive.
![Figure 6 Percent human beta- and alpha-cell proliferation in each islet graft recovered from control and lixisenatide-treated mice.](/cms/asset/4ba268a1-1c95-41a5-9918-387ac00a4945/dmso_a_87253_f0006_c.jpg)
Figure 7 Total beta- and alpha-cell counts in human islet grafts recovered from control and lixisenatide-treated mice.
Abbreviation: SEM, standard error of mean.
![Figure 7 Total beta- and alpha-cell counts in human islet grafts recovered from control and lixisenatide-treated mice.](/cms/asset/1820f936-0f02-419e-9afe-0088a95f9748/dmso_a_87253_f0007_b.jpg)
Figure 8 Photomicrographs of human islet grafts from control and lixisenatide-treated mice.
Abbreviation: DAPI, 4′,6-diamidino-2-phenylindole.
![Figure 8 Photomicrographs of human islet grafts from control and lixisenatide-treated mice.](/cms/asset/cfaa864e-ce94-4032-8dec-dbd8ad3099eb/dmso_a_87253_f0008_c.jpg)
Figure S1 Pharmacokinetic analysis of control and lixisenatide treatments.
Abbreviations: NSG, nonobese diabetic–severe combined immunodeficiency (NOD–scid) IL-2 receptor common gamma chain (IL-2rgnull); sc, subcutaneously; conc, concentration.
![Figure S1 Pharmacokinetic analysis of control and lixisenatide treatments.](/cms/asset/41e40217-3a3c-4656-a9d1-cd0350afe1a2/dmso_a_87253_f0009_c.gif)